-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
On March 22, Novo Nordisk issued an announcement stating that the company had received a notification of rejection (RFL) from the US FDA concerning semaglutide 2.
In this RFL, the FDA requested more information, including data related to the proposed new production site.
On January 20 this year, Novo Nordisk submitted a label extension application to the FDA to include a new dose of 2.
The label extension application for semaglutide 2.
The results showed that the study reached the primary endpoint: at the 40th week of treatment, using two evaluation methods, compared with the 1.
The SUSTAIN clinical project is evaluating weekly subcutaneous injections of semaglutide.
Reference source:
1.
2.